EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance and oncologic safety of sentinel lymph node biopsy after neoadjuvant chemotherapy: Results from a tertiary care center in Lebanon

Mariam Zahwe, Aya El Sammak, Karim Ataya, Christelle Jabbour, Ayman Bsat, Bassel Hafez, Christine Atallah, Mira Kheil, Mohamad Ali Maktabi, Bashar Hassan, Vahe Panossian, Hazem Assi iD und 2 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6868 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Mariam Zahwe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, American University of Beirut, Beirut, Lebanon. Hauptthemen laut MEDLINE: Sentinel Lymph Node Biopsy, Neoadjuvant Therapy, Tertiary Care Centers, Breast Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in initially node‐positive patients is still controversial. We aim to evaluate the oncologic outcomes of SLNB after NACT and further compare the results between those who were initially node‐negative and node‐positive.

Methods

This is a retrospective cohort that included patients diagnosed with invasive breast cancer and had surgical management between January 2010 and December 2016. Survival and recurrence data after 3–5 years were collected from patients' records. We divided patients into Group A who were initially node‐negative and had SLNB ± axillary lymph node dissection (ALND) and Group B who were node‐positive and had SLNB ± ALND.

Results

Among initially node‐negative patients, 43 out of 63 patients did SLNB (Group A). However, among initially node‐positive patients only 28 out of 123 patients did SLNB (Group B). Out of the 71 patients who did SLNB after NACT, 26 patients had positive SLNs with only 14 patients who further underwent ALND. The identification rate of SLNB was 100% in Group A and 96.4% in Group B. The survival curves by nodal status showed no significant difference between overall survival and recurrence‐free survival at 5 years between patients in Group A versus Group.

Conclusion

The results suggest that in properly selected patients, SLNB can be feasible after NACT. Our results resemble the reported literature on accuracy of SLNB after NACT and adds to the growing pool of data on this topic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sentinel Lymph Node BiopsyNeoadjuvant TherapyTertiary Care CentersBreast NeoplasmsHumansFemaleMiddle AgedLebanonRetrospective StudiesAdultAgedLymph Node ExcisionLymphatic MetastasisNeoplasm Recurrence, LocalAxillaChemotherapy, Adjuvant

Stichwörter der Autor:innen

breast cancerneoadjuvant therapysentinel lymph node biopsy

Autor:innen und Institutionen

  • Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
  • Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
  • Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
  • Faculty of Medicine, University of Balamand, Beirut, Lebanon.
  • Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.

ORCID-Profile: Hazem Assi, Eman Sbaity

Zitieren

APA

Zahwe, M., El Sammak, A., Ataya, K., Jabbour, C., Bsat, A., Hafez, B., Atallah, C., Kheil, M., Maktabi, M. A., Hassan, B., Panossian, V., Assi, H., Abbas, J., & Sbaity, E. (2024). Performance and oncologic safety of sentinel lymph node biopsy after neoadjuvant chemotherapy: Results from a tertiary care center in Lebanon. Cancer Medicine. https://doi.org/10.1002/cam4.6868

Vancouver

Zahwe M, El Sammak A, Ataya K, Jabbour C, Bsat A, Hafez B, et al. Performance and oncologic safety of sentinel lymph node biopsy after neoadjuvant chemotherapy: Results from a tertiary care center in Lebanon. Cancer Medicine. 2024. doi:10.1002/cam4.6868

BibTeX
@article{Zahwe2024,
  author = {Zahwe, Mariam and El Sammak, Aya and Ataya, Karim and Jabbour, Christelle and Bsat, Ayman and Hafez, Bassel and Atallah, Christine and Kheil, Mira and Maktabi, Mohamad Ali and Hassan, Bashar and Panossian, Vahe and Assi, Hazem and Abbas, Jaber and Sbaity, Eman},
  title = {Performance and oncologic safety of sentinel lymph node biopsy after neoadjuvant chemotherapy: Results from a tertiary care center in Lebanon},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6868}
}
Kostenlos starten →